留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

烟酰胺磷酸核糖转移酶的调控因素及药物作用

吕小群 张偌瑜 缪朝玉

吕小群, 张偌瑜, 缪朝玉. 烟酰胺磷酸核糖转移酶的调控因素及药物作用[J]. 药学实践与服务, 2011, 29(1): 11-14.
引用本文: 吕小群, 张偌瑜, 缪朝玉. 烟酰胺磷酸核糖转移酶的调控因素及药物作用[J]. 药学实践与服务, 2011, 29(1): 11-14.
LV Xiao-Qun, ZHANG Ruo-Yu, MIAO Chao-Yu. The regulatory factors and drug effects of nicotinamide phosphoribosyl transferase[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 11-14.
Citation: LV Xiao-Qun, ZHANG Ruo-Yu, MIAO Chao-Yu. The regulatory factors and drug effects of nicotinamide phosphoribosyl transferase[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 11-14.

烟酰胺磷酸核糖转移酶的调控因素及药物作用

基金项目: 国家973计划课题(2009CB521902);国家"重大新药创制"科技专项(2009ZX09303-002) ;上海市优秀学科带头人计划(10XD1405300);上海市血管生物学重点实验室开放课题基金(GXY2009001001).

The regulatory factors and drug effects of nicotinamide phosphoribosyl transferase

  • 摘要: 烟酰胺磷酸核糖转移酶(Nampt)是生命过程中不可或缺的蛋白,具有多种生理功能,对许多疾病如心脑血管疾病、糖尿病、癌症、自身免疫性疾病等有潜在的作用。阐明各种生理、病理状态以及化合物对Nampt表达水平的改变,可为Nampt的基础性和应用性研究起到推动作用。本文就各种因素对Nampt转录、表达调控的研究进展进行了较为系统的综述。
  • [1] Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005, 307(5708):426.
    [2] Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metabolism, 2007, 6(5):363.
    [3] Van der VE, Ho C, O'Neil C, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase[J]. Journal of Biological Chemistry, 2007, 282(15):10841.
    [4] Yang HY, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD(+) levels dictate cell survival[J]. Cell, 2007, 130(6):1095.
    [5] Kendal CE, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor (PBEF/visfatin) gene expression is modulated by NF-kB and AP-1 in human amniotic epithelial cells[J]. Placenta, 2007, 28(4):305.
    [6] Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity[J]. J Leukoc Biol, 2008, 83(4):804.
    [7] Wang T, Zhang X, Bheda P, et al. Structure of nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme[J]. Nat Struct Mol Biol, 2006, 13(7):661.
    [8] Frydelund-Larsen L, Akerstrom T, Nielsen S, et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise[J]. Am J Physiol Endocrinol Metab, 2007, 292(1):E24.
    [9] Pilz S, Mangge H, Obermayer-Pietsch B, et al. Visfatin/pre-B-cell colony-enhancing factor:a protein with various suggested functions[J]. J Endocrinol Invest, 2007, 30(2):138.
    [10] Ando H, Yanagihara H, Hayashi Y, et al. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue[J]. Endocrinology, 2005, 146(12):5631.
    [11] Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding[J]. J Clin Endocrinol Metab, 2006, 91(4):1578.
    [12] Sun G, Bishop J, Khalili S, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men[J]. Am J Clin Nutr, 2007, 85(2):399.
    [13] Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans[J]. J Clin EndocrinolMetab,2006, 91(8):3165.
    [14] Botella-Carretero JI, Luque-Ramirez M, lvarez-Blasco F, et al. The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery[J]. Obes Surg, 2008, 18(8):1000.
    [15] Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans[J]. Diabetes,2005,54(10):2911.
    [16] Hammarstedt A, Pihlajamaki J, Sopasakis VR, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones[J]. J Clin Endocrinol Metab, 2006, 91(3):1181.
    [17] Unluturk U, Harmanci A, Yildiz BO, et al. Dynamics of nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women[J]. Clin Endocrinol (Oxf),2009.
    [18] Segawa K, Fukuhara A, Hosogai N, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1α-dependent mechanism[J]. Biochem Biophys Res Commun, 2006, 349(3):875.
    [19] Bae SK, Kima SR, Kim JG, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1[J]. FEBS Lett, 2006, 580(17):4105.
    [20] Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization[J]. Circulation, 2007, 115(8):972.
    [21] Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer[J]. J Gastroenterol, 2009, 44(7):685.
    [22] De Boer JF, Bahr MJ, B?ker KH, et al. Plasma levels of PBEF/nampt/visfatin are decreased in patients with liver cirrhosis[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 296(2): G196.
    [23] Olesen UH, Christensen MK, Bjorkling F, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochemical and Biophysical Research Communications, 2008, 367(4):799.
    [24] Ognjanovic S, Bao S, Yamamoto SY, et al. Genomic organization of the gene coding for human pre-B-cell colony enhnancing factor and expression in human fetal membranes[J]. J Mol Endocrinol, 2001, 26(2):107.
    [25] Bauer L, Venz S, Junker H, et al. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1[J]. Int J Oncol, 2009, 35(1):97.
    [26] Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes[J]. J Endocrinol, 2005, 185(3):R1.
    [27] Ognjanovic S, Ku TL, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium[J]. Am J Obstet Gynecol, 2005, 193(1):273.
    [28] MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolicand sex hormones in 3T3-L1 pre-adipocytes and adipocytes[J]. Diabetes Obes Metab, 2007, 9(4):490.
    [29] Zhou H, Yang X, Wang NL, et al. Macrostemonoside A promotes visfatin expression in 3T3-L1 cells[J]. Biol Pharm Bull,2007,30(2):279.
    [30] Mukherjee S, Lekli I, Gurusamy N, et al. Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol[J]. Free Radic Biol Med, 2009, 46(5):573.
  • [1] 青胜利, 王淑娜, 汪东昇, 吕小群, 徐添颖, 缪朝玉.  肝脏特异性Nampt基因敲除对缺血性脑卒中的影响 . 药学实践与服务, 2022, 40(1): 12-19. doi: 10.12206/j.issn.1006-0111.202107068
    [2] 严啸东, 王业晴, 李炳锋, 郭美丽.  菸花苷对缺血性脑卒中大鼠的长期保护作用 . 药学实践与服务, 2022, 40(3): 226-230, 258. doi: 10.12206/j.issn.1006-0111.202201080
    [3] 王治, 王淑娜, 徐添颖, 李志勇, 张赛龙, 缪朝玉.  烟酰胺磷酸核糖转移酶基因编辑对人胚胎干细胞生长影响的研究 . 药学实践与服务, 2019, 37(3): 237-240. doi: 10.3969/j.issn.1006-0111.2019.03.009
    [4] 庞磊, 赵晶, 倪廷峻弘, 臧成旭, 丁子超, 张大志, 姜远英.  新型含喹啉和噻吩结构的抗真菌化合物的设计与合成 . 药学实践与服务, 2017, 35(1): 17-21,86. doi: 10.3969/j.issn.1006-0111.2017.01.005
    [5] 陈树强, 董国强, 盛春泉, 张万年.  活性小分子化合物靶点验证方法的研究进展 . 药学实践与服务, 2016, 34(2): 97-102. doi: 10.3969/j.issn.1006-0111.2016.02.001
    [6] 赵蕾, 赵雪梅, 唐辉, 吴娟.  新型喹唑啉酮类化合物合成工艺研究 . 药学实践与服务, 2015, 33(6): 529-532. doi: 10.3969/j.issn.1006-0111.2015.06.013
    [7] 冯世杰, 马秀娟, 宗英, 毛煜, 张晓冬, 弓雪莲, 张晓芳, 陆国才.  低氧诱导因子-1的病理生理及相关药物研究进展 . 药学实践与服务, 2014, 32(3): 161-166. doi: 10.3969/j.issn.1006-0111.2014.03.001
    [8] 李洋洋, 刘华, 刘宏, 张永强, 张万年, 盛春泉.  新型三唑类化合物的设计、合成和抗真菌活性研究 . 药学实践与服务, 2013, 31(1): 27-31. doi: 10.3969/j.issn.1006-0111.2013.01.008
    [9] 付丙月, 唐辉, 郑灿辉, 刘嘉, 周峰, 周有骏, 朱驹, 吕加国.  四氢萘类化合物合成工艺研究 . 药学实践与服务, 2012, 30(1): 35-37. doi: 10.3969/j.issn.1006-0111.2012.01.009
    [10] 王曙东, 陈兴东, 赵庆杰, 邹燕, 胡宏岗, 俞世冲, 汪亭, 柴晓云, 任海祥.  新型三唑醇类化合物的合成及抗真菌活性研究 . 药学实践与服务, 2011, 29(6): 426-430.
    [11] 刘彬果, 张新萍, 刘岩.  银杏叶中萜内酯类化合物的研究进展 . 药学实践与服务, 2011, 29(6): 421-425.
    [12] 吴广, 刘嘉, 牛春娟, 李科.  取代腺嘌呤类化合物的合成及其抗病毒活性研究 . 药学实践与服务, 2009, 27(6): 426-429.
    [13] 刘芳, 孙鹏, 李玲, 易杨华.  海洋抗病毒活性的小分子化合物研究概况 . 药学实践与服务, 2005, (3): 132-138.
    [14] 傅芃, 张川, 张卫东, 柳润辉, 徐希科.  呫吨酮类化合物的药理活性研究进展 . 药学实践与服务, 2005, (1): 6-12.
    [15] 邢旺兴, 程荣珍, 宓鹤鸣, 林培英, 陈士景, 吴玉田.  几种常见红曲霉的生理学特性研究 . 药学实践与服务, 2001, (4): 231-233.
    [16] 赵明强, 丁家宜.  植物培养物对外源化合物的糖基化 . 药学实践与服务, 2000, (5): 340-342.
    [17] 朱杰, 张万年, 季海涛.  喜树碱类化合物的构效关系及作用方式研究 . 药学实践与服务, 1999, (2): 71-74.
    [18] 鞠佃文, 李永福, 周廷森.  抗真菌治疗中的咪唑和三唑类化合物 . 药学实践与服务, 1991, (1): 4-7.
    [19] 汤海峰, 姜远英, 张紫洞.  TxA2的生理及病理作用 . 药学实践与服务, 1991, (4): 13-14.
    [20] 戴丽华, 徐爱民.  如何使用"近期化学文摘与化合物索引" . 药学实践与服务, 1988, (2): 77-79.
  • 加载中
计量
  • 文章访问数:  2148
  • HTML全文浏览量:  193
  • PDF下载量:  107
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-04-20
  • 修回日期:  2010-05-10

烟酰胺磷酸核糖转移酶的调控因素及药物作用

    基金项目:  国家973计划课题(2009CB521902);国家"重大新药创制"科技专项(2009ZX09303-002) ;上海市优秀学科带头人计划(10XD1405300);上海市血管生物学重点实验室开放课题基金(GXY2009001001).

摘要: 烟酰胺磷酸核糖转移酶(Nampt)是生命过程中不可或缺的蛋白,具有多种生理功能,对许多疾病如心脑血管疾病、糖尿病、癌症、自身免疫性疾病等有潜在的作用。阐明各种生理、病理状态以及化合物对Nampt表达水平的改变,可为Nampt的基础性和应用性研究起到推动作用。本文就各种因素对Nampt转录、表达调控的研究进展进行了较为系统的综述。

English Abstract

吕小群, 张偌瑜, 缪朝玉. 烟酰胺磷酸核糖转移酶的调控因素及药物作用[J]. 药学实践与服务, 2011, 29(1): 11-14.
引用本文: 吕小群, 张偌瑜, 缪朝玉. 烟酰胺磷酸核糖转移酶的调控因素及药物作用[J]. 药学实践与服务, 2011, 29(1): 11-14.
LV Xiao-Qun, ZHANG Ruo-Yu, MIAO Chao-Yu. The regulatory factors and drug effects of nicotinamide phosphoribosyl transferase[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 11-14.
Citation: LV Xiao-Qun, ZHANG Ruo-Yu, MIAO Chao-Yu. The regulatory factors and drug effects of nicotinamide phosphoribosyl transferase[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 11-14.
参考文献 (30)

目录

    /

    返回文章
    返回